Pzena Investment Management LLC Buys 1,625,494 Shares of Fresenius Medical Care AG & Co. KGaA $FMS

Pzena Investment Management LLC increased its stake in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 10.8% in the third quarter, Holdings Channel.com reports. The institutional investor owned 16,617,575 shares of the company’s stock after acquiring an additional 1,625,494 shares during the period. Fresenius Medical Care AG & Co. KGaA makes up about 1.1% of Pzena Investment Management LLC’s holdings, making the stock its 28th largest holding. Pzena Investment Management LLC’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $371,901,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Mather Group LLC. boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 838.0% during the third quarter. Mather Group LLC. now owns 1,407 shares of the company’s stock valued at $31,000 after acquiring an additional 1,257 shares during the period. Farther Finance Advisors LLC grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 39.1% during the third quarter. Farther Finance Advisors LLC now owns 1,915 shares of the company’s stock worth $43,000 after acquiring an additional 538 shares during the last quarter. Allworth Financial LP grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 31.5% during the second quarter. Allworth Financial LP now owns 3,552 shares of the company’s stock worth $80,000 after acquiring an additional 850 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the 2nd quarter worth about $91,000. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 50.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,135 shares of the company’s stock worth $93,000 after acquiring an additional 1,383 shares during the period. 8.37% of the stock is currently owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Trading Up 6.6%

Shares of FMS stock opened at $23.18 on Thursday. The stock has a 50-day simple moving average of $22.33 and a 200 day simple moving average of $22.88. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.02 and a fifty-two week high of $26.42. The stock has a market capitalization of $12.33 billion, a P/E ratio of 13.40, a P/E/G ratio of 5.07 and a beta of 0.78. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.43.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings results on Monday, August 3rd. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.23% and a return on equity of 9.03%. The firm had revenue of $5.55 billion for the quarter, compared to analysts’ expectations of $5.48 billion. On average, sell-side analysts expect that Fresenius Medical Care AG & Co. KGaA will post 2.24 earnings per share for the current fiscal year.

Analysts Set New Price Targets

FMS has been the topic of several recent research reports. Weiss Ratings upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Sanford C. Bernstein raised their price target on shares of Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the company a “market perform” rating in a research note on Thursday, August 6th. Berenberg Bank set a $24.00 price target on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, September 29th. Citigroup reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 17th. Finally, Zacks Research downgraded Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong sell” rating in a research report on Thursday, October 15th. Seven research analysts have rated the stock with a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat, Fresenius Medical Care AG & Co. KGaA has an average rating of “Reduce” and a consensus target price of $23.42.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney failure. The company provides dialysis care for patients with end-stage renal disease through a network of outpatient dialysis clinics and other health care facilities.

In addition to operating dialysis centers, Fresenius Medical Care develops and supplies products used in dialysis treatment. Its portfolio includes hemodialysis machines, dialyzers, dialysis solutions, bloodlines, and related medical devices and services.